Mangoceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Mangoceuticals generated cash of -$6,997,375, which is less than the previous year. Cash used in financing activities reached the amount of $7,057,040 last year. Net change in cash is therefore $56,146.
Cash Flow
| 2021 | -17.52K | 0 | 40.07K |
|---|---|---|---|
| 2022 | -1.34M | -43.10K | 2.04M |
| 2023 | -6.99M | -3.51K | 7.05M |
MGRX Cash Flow Statement (2021 – 2023)
| 2023 | 2022 | 2021 | |
|---|---|---|---|
Cash at beginning of period | 682.86K | 22.55K | 0 |
Operating activities | |||
Net income | -9.21M | -1.99M | -17.70K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||
Depreciation and amortization | 24.88K | 3.86K | 0 |
Stock-based compensation expense | 624.46K | 234.08K | 0 |
| Deferred income tax benefit | 624.46K | 234.08K | 0 |
| Changes in operating assets and liabilities: | |||
Accounts receivable, net | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 |
Accounts payable | 107.09K | 33.67K | 0 |
Cash generated by operating activities | -6.99M | -1.34M | -17.52K |
Investing activities | |||
Purchases Of Investments | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -3.51K | -43.10K | 0 |
Acquisitions Net | 0 | 0 | 0 |
Cash generated by investing activities | -3.51K | -43.10K | 0 |
Financing activities | |||
Common Stock Issued | 6.2M | 2M | 800 |
Payments for dividends | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 |
Repayments of term debt | -167.46K | 49.93K | -39.27K |
Cash used in financing activities | 7.05M | 2.04M | 40.07K |
Net Change In Cash | 56.14K | 660.31K | 22.55K |
Cash at end of period | 739.00K | 682.86K | 22.55K |
| Data source |